Generate Biomedicines, Inc. Interest Expense Nonoperating
Generate Biomedicines, Inc. (GENB) reported Interest Expense Nonoperating of $155.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Generate Biomedicines, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $155.00K, a 49.51% decline year-over-year.
- Generate Biomedicines, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $182.00K, a 50.54% decline year-over-year.
- Generate Biomedicines, Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $307.00K.
- Generate Biomedicines, Inc. interest expense nonoperating for the quarter ending 2025-03-31 was $368.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month |
|---|---|---|
| 2026-06-30 | $155.00K 10-Q · filed 2026-08-06 | $337.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $182.00K 10-Q · filed 2026-05-07 | |
| 2025-06-30 | $307.00K 10-Q · filed 2026-08-06 | $675.00K 10-Q · filed 2026-08-06 |
| 2025-03-31 | $368.00K 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |